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ABSTRACT
Ending the HIV/AIDS epidemic by 2030 is a global agenda. To meet this global 
goal, having safe and effective antiretroviral therapy is a key requirement. In 
Ethiopia, the safety and efficacy of combination antiretroviral therapy in HIV 
infected pediatric population is poorly studied. In this thesis, I aimed at understand-
ing the short- and long-term safety and efficacy of antiretroviral therapy among 
HIV infected children in Ethiopia. Clinical and laboratory data were recorded for 
a total of 870 HIV infected children in two parallel cohorts – EPDOS and EPHIC 
projects. 
We first investigated the burden and correlates of pretreatment drug resistance 
(PDR) in Paper I. We observed that the overall rate of PDR was 14%. All cases 
with PDR had resistance to NNRTIs while ~9% harbored resistance solely to 
NNRTIs and ~5% harbored resistance to both NNRTIs and NRTIs. No resistance 
was observed to protease inhibitors. 
In Paper II, among children who were followed for 48 weeks following initiation 
of treatment, we assessed virologic outcome of children at one year of cART ini-
tiation using Cox Proportional Hazards Model. In total, 94/110 (85.5%) achieved 
virological suppression to undetectable levels during the first year of treatment. 
Thirty-six (31.9%) experienced virologic rebound. Tenofovir-containing cART 
regimen and absence of PDR were associated with higher virologic suppression.
In Paper III, we explored burden and correlates of HIV drug resistance among 
children who failed treatment. Overall, 81% (73/90) of successfully genotyped 
participants had resistant mutations. From these, 69% (62/90) harbored dual drug 
class resistance. Strikingly, 42% of the participants harbored resistance to all 
four NRTIs recommended for second line use in the setting. Longer duration of 
cART and any regimen changes were associated with occurrence of drug resist-
ance mutations. 
In Paper IV, we investigated the long term renal and hepatic toxicities associ-
ated with antiretroviral therapy among cART experienced children. At study 
enrolment, 177(25.1%) and 83(11.8%) had high aspartate aminotransferase and 
alanine amino transferase (ALT), respectively. Zidovudine or nevirapine contain-
ing regimens and viral load >1000 copies/mL were associated with elevated ALT. 
Twenty-four (3.4%) and 84(12.1%) of the children had elevated creatinine and 
blood urea nitrogen (BUN), respectively. A progressive increment in BUN and 
decrement in GFR were observed during the follow up period. Both AST and ALT 
exhibited a decreasing trend.
In Paper V, we compared the prevalence and correlates of dyslipidemia between 
cART naïve and experienced HIV infected children. Dyslipidemia was more com-
mon among cART experienced (70.2%) than naïve (58.1%) HIV infected children 
(p=0.03). Higher proportion of low HDLc (40.2% versus 23.4%, p=0.006) and 
hypertriglyceridemia (47.2% versus 35.8%, p= 0.02) was observed among cART 
experienced HIV infected children as compared to naïve. No difference was 
observed in the proportion of total hypercholesterolemia and high LDLc levels 
between the groups. Undernutrition was associated with more dyslipidemia in the 
cART naïve group (p=0.01). 
In conclusion, we showed that a high proportion of children with HIV infection in 
resource-limited settings do achieve virologic suppression during the first year of 
treatment initiation. We also confirmed that HIV drug resistance is a major cause 
of virologic treatment failure in children with limited virologic monitoring. On 
the other hand, the burden of PDR is low but predicts virologic outcome. Adverse 
events associated with cART are the major challenges for meeting the global 
UNAIDS targets in 2020 and 2030. The findings call for targeted monitoring and 
treatment of children in resource-limited settings. 
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11 INTRODUCTION
HIV infection is one of the devastating epidemics that mankind has ever faced in 
the 21st century. The first cases of HIV have been reported in 1981 after young 
previously health gay men presented with rare cases of lung infections in the 
USA [1]. Afterwards, the HIV epidemic has grown very fast, and HIV has been 
responsible for claiming millions of lives over the past four decades. As of 2017, 
there are around 37 million people who are living with HIV, the number has been 
steadily increasing with slight plateauing over the past 15 years, which could be 
attributable to the prevention and control efforts by the global community. The 
incidence of new HIV infections has been decreasing over the past 20 years – with 
3.4 million (range: 2.6 to 4.4 million) infections per year in 1995 to 1.8 million 
(range: 1.4 to 2.4 million) infections per year in 2017 [2].
Sub Saharan Africa has the highest burden of HIV/AIDS with significant regional and 
sub national variations in the prevalence and transmission dynamics of the virus [3]. 
The East and southern Africa (ESA) region is the hardest hit by the HIV epidemic. 
The majority of the HIV infected population lives in the ESA region – in the region, 
19.6 million people live with HIV with 800 thousand new HIV infections per year 
and an adult prevalence of 6.8% [4].The impact of HIV/AIDS in ESA is profound – 
HIV has created a huge burden on the health system and is also a significant social 
and economic hurdle to the governments and the society as a whole [5]. 
The overwhelming response by the global community and the huge expenditure 
by funders to the HIV epidemic are the reasons for success achieved in reducing 
HIV morbidity, mortality and control the spread of the epidemic. Funding for 
HIV has increased from around $5 billion in 2000 to more than 20 billion in 2017 
[2, 6]. A sustained support for HIV prevention and control from the Global Fund, 
 especially targeting high burden and low-income countries, is one of the strate-
gies that largely contributed to curbing the HIV epidemic in high burden settings. 
However, it was also noted that the most at risk population including children was 
not properly prioritized in most of these settings [7].
The overall HIV/AIDS related mortality halved over the past decade – it decreased 
from an average of 1.9 million deaths per year in 2005 to 940 thousand in 2017 
[2, 8]. Effective combination antiretroviral therapy (cART) is key to sustained 
virological suppression and hence decreased morbidity and mortality. Access to 
treatment has improved significantly following global initiatives like 90-90-90 
goals and the “ending the AIDS epidemic in 2030” [9, 10]. The 90-90-90 goals 
aim that 90% of patients who have HIV infection get diagnosed for HIV; 90% of 
those who know their status initiate cART; and, 90% of those who are on cART 
maintain virological suppression. In response to these global targets, the national 
and international efforts have led to a cART coverage of 79%, and 81% of those 
who have been initiated on cART are virologically suppressed globally [2]. 
2Figures 1-3 show the overall prevalence, incidence and mortality of HIV infection 
among all ages and sexes, which were published in the Global Burden of Diseases 
report in August 2019 [11].
Figure 1. Global incidence of HIV infection among the general population as of 2017.
Source: Global Burden of Diseases (GBD) report, 2019 [11].
Figure 2. Global prevalence of HIV infection in all ages and sexes, 2017.
Source: Global Burden of Diseases (GBD) report, 2019 [11].
Figure 3. HIVAIDS associated mortality among all ages and sexes, 2017.
Source: Global Burden of Diseases (GBD) report, 2019 [11].
31.1 The HIV Epidemic in Children
1.1.1 Overview of Pediatric HIV infection 
The history of pediatric HIV/AIDS starts back in 1982 when the CDC reports 22 
cases of infants with HIV infection after receiving blood transfusion and with the 
first recommendations to prevent mother to child transmission of HIV coming 
out in the USA in 1985 [12]. Nearly three decades after the first cases of pediatric 
HIV have been reported, currently 1.7 million [1.3 million–2.2 million] children 
live with HIV [13]. The history of pediatric HIV in Ethiopia likely corresponds 
with the introduction of the HIV virus in the country where the virus might have 
been first introduced in the 1980s according to genetic diversification studies [14]. 
In the early 1980s when the burden of HIV in the general population was still 
low, one of the main ways of viral transmission was mother to child transmission 
(MTCT) leading to the first cases of pediatric HIV cases [15]. 
Children and adolescents constitute a unique group of the HIV infected popu-
lation and require evidence-based approaches to care and treatment decisions 
[16]. Pediatric HIV care and treatment progress indicators often lag behind 
those for HIV infected adults and are associated with several bottlenecks, chal-
lenges and opportunities [17, 18]. More alarmingly, the UNAIDS further warns 
that the gains made among the pediatric population are slowing [17].The fear is 
evidenced by the decline in new HIV infections from 2017 to 2018 of less than 
10%; and, that only 52% of children who live with HIV infection had received 
combination antiretroviral therapy, which is lower than the adult figure (60%) [9, 
17]. Moreover, there were 110 000 AIDS-related child deaths in 2017. In 2017, 
despite the high prevention of mother to child transmission (PMTCT) coverage of 
80% –  indicating the prevalence of pregnant women who had access to cART for 
PMTCT purposes,180,000 children were newly infected with HIV either during 
pregnancy, birth or breastfeeding [17]. This figure is far from the UNAIDS target 
of 40 000 or fewer by the end of the year 2018 [17].
To improve the care and treatment of HIV infected children, the priority agenda 
for further action might include improving linkage to care, adherence to treat-
ment and optimizing long and short-term outcomes of cART [19]. Management 
of antiretroviral therapy associated adverse events, retention to care, psychosocial 
support and improving disclosure of HIV status have also been key areas of focus 
for pediatric HIV care and treatment [19, 20].
1.1.2 Pathogenesis of HIV in children
HIV infection outcomes generally depend on integrity and maturity of the innate 
and adaptive immune systems. Children who acquire HIV infection vertically from 
an HIV infected mother have an immature immunity at an earlier age, specifi-
cally the adaptive/specific immunity is immature exhibiting no recall to previous 
4exposure of antigens [21]. Natural killer cells (NK), plasmacytoid and dendritic 
cells were reported to have significant impairments in both number and function 
among perinatally HIV infected children [21, 22]. The main players of the HIV 
infection pathogenesis are a sub set of the CD8+ T-lymphocyte population who 
produce cytokines and chemokines that have effect on viral infections; and, the 
CD4+ T-lymphocyte population which is critical for supporting antibody produc-
tion and mediating the cytotoxic T-lymphocyte responses [23, 24]. This underlines 
the need for focusing on preserving these cell lines to ensure virologic suppression 
and low morbidity/mortality.
Among perinatlly HIV infected children, a bimodal distribution of HIV progres-
sion and symptomatology was described in the developing world – with faster 
progression observed among those with in uterine infection compared to those who 
acquired infection postnatally [25, 26]. In addition to the time when HIV infec-
tion was acquired, gestational age and maternal health status [27], age appropriate 
CD4+ T-lymphocyte count, and HIV virus characteristics [28] were described as 
major predictors of death and disease progression among vertically HIV infected 
children [29]. 
The dynamics of HIV infection among perinatally infected children has been well 
described – with the availability of quantitative HIV-1 RNA polymerase chain 
reaction (PCR)[30-32]. Several studies documented the relevance of viral load 
on disease progression, early childhood mortality, and response to antiretroviral 
therapy where a higher baseline viral load is associated with poorer treatment 
outcomes [32-36]. 
Overall, the probability of vertical transmission of HIV without any PMTCT inter-
vention is between 20% and 45%. From this aggregate, mother to child transmission 
(MTCT), 5-10% of the infections occur in utero; 10-20% happen intrapartum; and, 
5-20% occur through breastfeeding [37].The natural history of HIV also depends 
on the time of acquisition of HIV infection – whether, intrapartum or during 
breast feeding. Without early antiretroviral therapy, about 25-30% of perinatally 
HIV infected children are rapid progressors most of whom die before celebrating 
their first birthday. This group of children most likely acquires HIV infection in 
utero or during the early post-natal period. The majority of vertically HIV infected 
 children become symptomatic during the early years of life and most (50-60%) die 
before celebrating their fifth birthday. A smaller group (5-25%) continue to become 
long term survivors and live beyond 8 years of age. These children tend to have 
lymphocytic interstitial pneumonitis and have poor anthropometric z scores [37].
51.1.3 Burden of Pediatric HIV in Ethiopia
Ethiopia is one of the high burden countries in the sub Saharan African region, 
which constitutes about 80% of the total HIV infections worldwide [38]. The overall 
prevalence of HIV infection in Ethiopia is around 1% (with a large variation by 
geographical area – 2.9% urban versus 0.4% rural prevalence); and, incidence rate 
of 0.33/1000 population. An estimated 610,000 (470 000 – 780 000) people live 
with HIV as of 2017 [39, 40]. In 2017, there are 62 000 (38 000 – 86 000) children 
younger than 14 years living with HIV; and, nearly 5 500 (2 600 – 8 800) new 
HIV infections occur annually in children less than 14 years of age [40]. Around 
3 600 (1 800 – 5 800) deaths in children and 330 000 (220 000 – 460 000) orphans 
were attributed to HIV infection [40].
When we closely look at the trend of HIV infections in Ethiopia over the past 20 
years, the prevalence of new infections declined by more than 80% during the first 
10 years from 2000-2010. However, during the second decade, the HIV incidence 
rate started to increase by 10% yearly and the total number of new HIV infections 
increased by more than one third [41, 42]. The reversal of the gains in control-
ling the HIV pandemic in the country is basically associated with the weakening 
of national programs which were designed to control the epidemic. Particularly, 
in recent years, the surge in the prevalence and transmission of HIV in the town-
ships has been reported to be worrisome [39, 41]. There is a need to strengthen 
and sustain the educational, advocacy and testing programs nationally to maintain 
the success achieved in controlling the HIV epidemic in the country. Overall, HIV 
still appears to be a huge burden as a cause of child morbidity and mortality, and 
the already weak health system and economy of the country are under pressure.
1.1.4 Diagnosis of HIV infection in children in Ethiopia
Diagnosis of HIV in children is complicated by the passage of HIV antibodies from 
the HIV infected mother to her baby; and, hence the presence of HIV antibodies 
in the baby cannot be used for diagnosis [43]. Routine rapid antibody testing is 
recommended for all infants and mothers living in a setting where the prevalence of 
HIV is >1% [44]. Virologic testing should be done for all infants who are exposed 
to HIV at 4 to 6 weeks of age, as these children will need to be on antiretroviral 
treatment as early as possible [45]. Nucleic acid tests [NATs] which include HIV 
RNA and HIV DNA PCR assays are key to diagnose HIV infection in infants. A 
positive first test requires a repeat virologic testing on another specimen as there 
could be false positive results with several RNA and DNA assays [46].
Diagnosis of HIV infection in infants and children can be done using clinical, immu-
nologic and virological parameters (see Table 1). In the absence of virologic tests 
that can confirm HIV infection, in infants with HIV exposure, clinical criteria can 
6be used to make a diagnosis of presumptive severe HIV infection [47]. Specifically, 
an HIV exposed infant who develops severe sepsis, candida infection and chronic 
or persistent diarrhea is considered a case of severe presumptive HIV infection. 
Table 1. Summary of the methods of diagnosis of HIV infection in children 
Diagnostic Method Advantage Limitation 
Clinical Suspicion of 
HIV diagnosis – diag-
nosis of Presumptive 
Severe HIV Infection 
- Used in young infants who 
were exposed to HIV infection 
- Is used when there is limited 
access to virologic tests to 
confirm infection among <18 
month children [47]
- Easy to do, readily available 
and cost effective 
- Low sensitivity and secficity 
[48]
- Leads to treatment dis-
continuation in children with 
other diagnosis 
Antibody tests - Can be used to confirm 
infeciton for children >18 
months 
- Can also be sued to rule out 
infection among <18 month 
children [49].
- Cheap and easily accessible
- Can not be used to make 
 disgnosis of HIV in children 
<18 months 
Virologic tests – HIV 
DNA or RNA PCR 
and other antigenic 
tests 
- Can be used to confirm 
 infection among HIV exposed 
infants and children <18 
months 
- Has high sensitivity and 
specificity 
- Not affected by HIV anti-
bodies transferred from 
the mother 
- Expensisve and unavailable 
in most resource constrained 
settings 
1.1.5 Pediatric HIV treatment in Ethiopia
Combination antiretroviral therapy (cART) has dramatically changed the natural 
history of HIV/AIDS, once a fatal disease has changed to a chronic illness. In 
2014, UNAIDS set the 90-90-90 goals to be achieved by 2020 [50]. Following 
these efforts, the coverage of cART is increasing dramatically – as of 2018, nearly 
80% of those who knew their HIV status could access treatment [40]. This is a 
significant progress compared to the 2016 UNAIDS report of around 50% access-
ing treatment [51]. 
Ethiopia has a remarkable progress towards the 90-90-90 targets, particularly in 
the first two 90´s. Seventy three percent of those who live with HIV know their 
status and 71% of those who know their status are on care and treatment [40]. 
However, the progress towards achieving the third 90 of achieving 90% virological 
7suppression among those who are on treatment is still lagging behind at around 
32%. This figure is much lower than the international average of 81% virological 
supersession among those who initiated cART[40]. Even though the achievement 
is remarkable for adults, the coverage of cART access in children is only 34%, and 
only 21 385 children are on cART by 2017, which is around only a third [39, 40]. 
Based on guidelines from the World Health Organization (WHO), for children 
three years and older, the preferred first line combination includes two nucleoside 
reverse transcriptase inhibitors (NRTI) and one non-nucleoside reverse transcriptase 
inhibitors (NNRTI) – namely, Abacavir/Tenofovir, Lamivudine and Efavirenz 
(EFV) [52]. The current recommendation is to start all HIV infected children 
and adolescents on cART irrespective of clinical and laboratory parameters. The 
current recommendation by the WHO includes initiating cART with a protease 
inhibitor (PI)–based regimen for all children who are younger than three years 
since several studies indicated a high level of pre-treatment HIVDR, especially 
in children with PMTCT exposure [52, 53]. Specifically, the recommended first 
line cART for children 3 to 10 years is Abacavir (ABC), Lamivudine (3TC) and 
EFV. There are multiple alternative regimens for this age group – the 3TC back-
bone is usually the same with a combination of Zidovudine (AZT) or Tenofovir 
(TDF) replacing the NRTI by ABC. For the NNRTI wing, Nevirapine (NVP) can 
be used instead of EFV [52].
The adolescent first line cART regimen includes TDF as a preferred NRTI, 3TC 
as a backbone and EFV as a preferred NNRTI. As alternatives, Emtricitabine 
could be used as an alternative to 3TC, and Dolutegravir (DTG) and a lower dose 
of EFV (EFV400) instead of the higher dose (EFV600) – are considered as addi-
tional alternatives to the NNRTI. However, the guidelines highlight that safety 
and efficacy data are lacking for the use of DTG and EFV400 among pregnant 
women, in cases of HIV/TB co-infection and among adolescents <12 years of age 
[52]. DTG is considered a very promising alternative to NNRTIs owing to its low 
resistance potential, excellent safety, efficacy and low cost [54-56]. Similarly, for 
adults, EFV400 has been reported to be a compelling alternative compared to the 
standard dose of EFV (EFV600) owing to its non-inferior efficacy, few adverse 
events and its cost effectiveness [57-59].
1.2 Pediatric HIV Treatment Outcomes
Earlier studies have indicated the feasibility to do a largescale HIV care and treat-
ment scale up in settings where there is limitation of resources [60]. HIV treatment 
has resulted in remarkable success in reducing HIV and opportunistic infection 
related child deaths [61, 62]. However, the effect of cART on child survival indi-
cators could be compromised by poor adherence, high attrition and late diagnosis 
8of HIV infection [60, 63-65]. Children who are on long term cART who live in 
resource limited settings still have a higher mortality. Specifically, children who 
have malnutrition at treatment initiation and poor immunologic status were also 
associated with increased mortality while on cART[64, 66]. 
In Ethiopia, there has been a significant achievement in scaling up HIV treatment 
and care for infected children and adolescents but retention to care is still a big 
challenge [67]. As of 2013, more than 11,000 children were enrolled to HIV care 
and treatment while nearly two-third of them were initiated on antiretroviral therapy 
[67]. After scale of cART for HIV infected children, HIV associated mortality has 
decreased in Ethiopia – a reduction from 20.1 to 16.6 deaths per 100,000 popula-
tion from 1990 to 2013[68]. However, reports also show that there is a high child 
mortality while on antiretroviral therapy [64]. 
1.2.1 Virological outcome following initiation of cART
Virological outcomes of children receiving antiretroviral therapy are one of the 
indicators of the 90-90-90 global goal by the year 2020. Briefly, the goal is for 
90% of the children on cART to be virologically suppressed [50]. Virologic out-
comes among HIV infected children on treatment from the developed settings 
were reported to be comparable to other populations [69]. However, even in such 
settings subgroups of children might suffer a poor outcome. For example, in a 
European cohort, young children below the age of 2 years were found to have the 
poorest virologic outcome [70]. Similar findings on the effect of age on virologic 
outcome was reported from Asia [69]. 
Early virologic outcomes among children on cART living in resource limited 
 settings were reported to be optimal [71]. Even though, the varying thresholds 
used by studies for the definition of virological suppression could complicate 
comparisons, viral suppression of 70-90% has been reported by different studies 
[72, 73]. A Kenyan study reported that male sex and drug substitution were linked 
to poor virological suppression among HIV infected children [74]. 
1.2.2 First-line treatment failure and predictors in Ethiopia
While initiation of cART has improved outcomes in HIV infected children [75], 
factors including HIV drug resistance, and long-term cART associated metabolic 
disorders which increase the risk of early treatment failure have emerged as threats 
to the long term durability. These factors compromise the impact of cART on 
child morbidity and mortality. Acute and chronic HIV adverse drug events and 
non-communicable diseases such as diabetics and cardiovascular disorders could 
negatively affect long term cART outcomes of HIV infected children [76].
9In children, durability of cART regimens can be as short as six months to a  couple 
of years and depends on several factors including adherence, genetics, prior cART 
exposure, HIV drug resistance (HIVDR) and age [66, 77]. In Ethiopia, local data 
on treatment outcomes reported a variable prevalence of 4-17.5% treatment failure 
among adults using immunological criteria [78]. In children, there is scarcity of data 
measuring treatment outcomes; however, the available data suggest that 5.9% and 
6.7% clinical and immunologic cART failure rates were reported, respectively [66]. 
Treatment outcomes to cART can be measured using clinical, immunological or 
virological parameters at least 6 months after treatment has been initiated [45, 52]. 
Even though viral load testing has been considered as the gold standard in the 
diagnosis of treatment failure, the test remains to be costly, technically  demanding 
which limits its applicability in resource poor settings. In resource-constrained 
settings, viral load determination cannot be readily used to make a diagnosis of 
treatment failure. Ethiopia has made significant progress in availing viral load 
testing at regional laboratories as part of the effort to meet the 90-90-90 goals in 
virological suppression. Short of viral load monitoring, cART outcomes are assessed 
using the imperfect clinical and immunologic criteria which are suggested by the 
WHO guidelines [45, 52].
Several sociodemographic, cART associated, and immunologic factors have been 
reported to predict the occurrence of first-line treatment failure among children and 
adolescents. From the sociodemographic predictors, child’s age [66, 79-82], child’s 
sex [66, 80], parental status, specifically being an orphan [83] have been found 
to predict occurrence of first line cART regimen failure. Moreover, cART related 
variables including duration of antiretroviral therapy [83], sub optimal adherence 
to antiretroviral therapy [66, 84-87], being on a nevirapine (NVP)-containing 
first line cART regimen [81, 88], drug substitution during therapy [66] and drug 
adverse events [66, 84, 85] were associated higher risk of treatment failure. Child 
related factors including undernutrition [66], low baseline CD4 count [66, 81, 82, 
84, 87, 89], and advanced WHO clinical stage [66, 84, 87, 90] were also reported 
to increase the chance of failing while on first line cART. Presence of any form of 
tuberculosis co-infection also increased the likelihood of treatment failure among 
HIV infected children [87, 90]. 
1.2.3 Impact of HIV drug resistance on treatment success
The introduction and scale up of cART in children including for purposes of pre-
vention of mother-to-child transmission (PMTCT) is a significant stride towards 
improving survival and quality of life of children in resource-limited countries 
[91, 92]. With the improving access to PMTCT, mother to child transmission rates 
have gone down significantly. However, children for whom the PMTCT interven-
tions did not work and unfortunately get infected are at a particularly high risk of 
developing HIVDR [93, 94]. 
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The ultimate goal of antiretroviral therapies is virological suppression and immu-
nologic restoration. However, the current drugs cannot eradicate the virus from 
reservoir tissues – suboptimal exposure due to poor adherence would lead to 
evolvement of selective mutation to the antiretroviral drugs [95-97]. The error 
prone reverse transcription of HIV virus, the very high replication and mutation rate 
make HIV prone to having frequent resistance mutations [95]. There are different 
approaches to resistance testing including phenotypic, genotypic, resistance testing 
in clinical practice and minority drug resistance variants testing [98]. Generally, 
genotypic resistance testing is considered a more sensitive method of detecting 
resistance mutations compared to the phenotypic method. Based on how and when 
it  develops, HIV drug resistance can be acquired because of suboptimal treatments 
and medication nonadherence (ADC) or transmitted at the time of infection (TDR). 
The pooled prevalence of HIV drug resistance mutations across African  countries 
is 10.6% with the highest prevalence of 54.9% from central Africa [99]. The major 
NRTI inhibitor mutation in most African countries was found to be M184V. NNRTI 
inhibitor mutations were found to be the highest in the Eastern African region, 
reaching as high as half of the cases screened. On the other hand, the major NNRTI 
and PI inhibitor mutations varied by region [99]. 
There is a recent concern on the increment in the prevalence of pretreatment 
or transmitted HIV drug resistance among children especially those exposed to 
PMTCT. For instance, in a recent review on pre-treatment HIV drug resistance, 
it is indicated that there is an alarming increment in the rate of pre-treatment 
HIV drug resistance (PDR) among children over the past years [100]. The same 
review showed a much higher prevalence of resistance among those who had no 
PMTCT exposure (42.7%) compared to the unexposed ones (12.7%). Increment 
in pre-treatment drug resistance by more than a quarter was observed over the 
past ten years among PMTCT-unexposed children [100]. A 2014 review showed 
a resistance level in NRTIs to be 0% to 100%; NNRTIs, 3.3% to 100%; and PIs, 
0% to 66.7% among pre-treated children globally [101].
A decade back data on HIV drug resistance in Ethiopia were limited [102]. 
Nevertheless, there are recent reports that indicate the burden of HIV drug resist-
ance in the country. A recent analysis from the Northwest of the country showed 
a 6.0% PDR mutations prevalence among cART naïve adult patients (n=67) – all 
the mutations were associated with NNRTI [103]. Another nationwide surveil-
lance study reported a lower prevalence of 3.9% TDR mutations among treatment 
naïve adult HIV patients [104]. In 2015, the prevalence of acquired drug resistance 
was reported to be low at around 5% despite many years of cART roll out. Major 
NNRTI resistance mutations including K103N, V106M and Y181M; and, major 
NRTI mutations like M184V and K65R were reported in the same study. There 
were no PI and Thymidine analogue resistance mutations observed in the cohort 
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[105]. However, a recent trend analysis indicated that the prevalence of acquired 
HIV drug resistance mutations increased steeply – it increased from 40% to 66% 
in 10 years. M184V was the most frequent NRTI-associated drug resistance muta-
tion; thymidine analogue mutations like D67N, K70R and K219E; and, NNRTI 
associated drug resistance mutations like K103N, V106M and Y188C [106].
In settings where HIV drug resistance screening is an integral part of the routine 
care, HIVDR is useful for individual patient treatment; however, in LMICs where 
these services are not readily available, generating evidence on the mechanisms and 
implications of HIVDR might be useful for surveillance and for targeted individual 
patient treatment [107, 108]. There is still scarcity of data on the level and predic-
tors of HIVDR among children and adolescents in LMICs especially in Africa. 
1.2.4 Drug adverse events affecting treatment outcome
Renal and Liver Toxicity
HIV infection itself or the adverse effects related to the antiretroviral drugs could 
have deleterious effects on the kidneys and the liver. However, characterization of 
drug induced hepatotoxicity and drug-induced liver disease (DILI) among children 
with HIV infection is not well described with incompletely understood patho-
physiologic processes. Even though elevated bilirubin and alkaline phosphatase 
indicate a cholestatic form of liver disease, the liver enzymes (aminotransferases) 
are often considered to be markers of liver injury [109, 110]. The definition requires 
meticulous follow-up based on the markers of liver injury, synthetic function and 
hepatic imaging when deemed necessary [111, 112]. The burden, pathophysiology 
and definition of renal adverse events among HIV-infected children also remains 
incompletely studied [113].
Liver abnormalities related to the HIV infection and/or antiretroviral therapy can 
present with high transaminase levels, jaundice and hyperbilirubinemia, abdominal 
symptoms like abdominal pain, or even fulminant liver failure [114, 115]. The mag-
nitude of hepatotoxicity within the first three months of cART in adults were found 
to be low at 1-2%, with an incidence rate of 4 to 8 patients with hepatotoxicity per 
hundred person years. The same data also reported that there is no increased risk 
of mortality associated with development of hepatotoxicity within three months 
of initiation of cART [116]. Contrary to this, a much higher proportion (32%) of 
HIV infected adults on treatment had transaminase elevation in Ethiopia [117]. 
Adults with tuberculosis (TB) and HIV co-infection on cART and anti-TB had a 
much higher incidence of hepatotoxicity (30%) compared to HIV infected adults 
on cART only (15,7%) [118, 119].
Liver toxicity is the commonest adverse event in HIV infected children who are 
on cART [120]. Generally, children with HIV infection who are on treatment were 
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reported to have markedly higher prevalence (~16-20%) of liver toxicity com-
pared to HIV infected adults taking cART [120-122]. Progressive improvement in 
elevated transaminases was reported as children were longer on cART. Resolution 
of hepatotoxicity marked by normalization of liver enzyme levels was shown to 
be at around 3 to 6 months of treatment [123]. The adverse events of antiretroviral 
therapy on hepatic functions in children are not clearly understood, especially for 
sub-Saharan African children where cART scale up is considered a recent success. 
HIV infection and cART could also cause impaired kidney function and other 
problems – including nephrolithiasis, tubular acidosis and renal failure – among 
children and adolescents. The mechanism of kidney injury and renal function 
abnormalities could be related to immune mediated mechanisms, also called HIV-
Associated Nephropathy (HIVAN); and, adverse events of cART which could 
also be responsible for kidney injury [124]. Hence, renal function of children and 
adolescents living with HIV could be compromised by both the HIV infection 
and cART drugs. 
Dyslipidemia and Metabolic Adverse Events
Adverse events which could be acute or long term might lead to decreased HIV 
drug efficacy and hence increased child mortality. Lactic acidosis, lipodystrophy, 
dyslipidemia and insulin resistance have been described as potential metabolic 
adverse events among both children and adults who have been on long term cART 
[125], though data on the magnitude of the problem among children in resource 
limited settings is scanty [126]. In a cohort of adults from Australia, 46.3% had 
some level of dyslipidemia and observed more among those taking protease inhibi-
tor containing regimens [127]. 
In children, dyslipidemia was reported in 38.3% while a majority (80.2%) had 
some form of lipodystrophy and no significant clinical associations were identi-
fied [128]. Longer time on HIV treatment was liked with higher rate of insulin 
resistance, and yet children on AZT or ABC containing cART were even more 
likely to have a higher probability of insulin resistance [129]. The general burden 
of dyslipidemia was reported to be 10-15% [129, 130]. These observations call for 
further studies to understand the magnitude of dyslipidemia and design preventive 
strategies as children live longer on cART. 
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2 AIMS OF THE RESEARCH
The general objective of the PhD research was optimizing antiretroviral therapy for 
children with HIV infection who live in resource limited settings through i) improved 
understanding of virologic outcome following initiation of cART and identifying 
factors associated with unfavorable treatment outcome, ii) assessing the prevalence 
and predictors adverse events associated with short and long term cART for targeted 
intervention, care, and implementation of preventive strategies. Overall, the PhD 
research aimed to assess the safety and efficacy of the recommended first line regi-
mens among HIV-infected children. 
2.1 Specific Aims
The specific objectives of the PhD research focused on efficacy and safety of 
cART regimens for children from a high HIV prevalence but with limited treatment 
options and scarce virologic monitoring settings. The specific objectives were:
1. To determine the prevalence and associations of pretreatment HIV drug 
 resistance (PDR) among newly diagnosed HIV infected Ethiopian children 
(Paper I).
2. To assess virologic outcome and its predictors during the first year of cART 
among newly diagnosed HIV-infected children living in a resource limited 
setting (Paper II).
3. To determine the prevalence and correlates of HIV drug resistance as a cause 
of first line cART failure among HIV infected children on first line treatment 
regmin (Paper III).
4. To assess long and short term adverse events asscoiated with cART among HIV 
infected children in a resource limted setting with limited viral load monitoring. 
We assessed two inportant potential adverse events under this specific objecitve:
4.1. To determine renal and hepatic tocixicty and associated factors among 
children who were on long term cART (Paper IV)
4.2. To assess the prevalence and correlates of dysipidemia associated with 
cART and HIV infection (Paper V).
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3 MATERIALS AND METHODS
The data for the PhD research were obtained from two parallel HIV infected pedi-
atric cohorts which enrolled a total of 870 children – the first was the Ethiopian 
Pediatric HIV Cohort (EPHIC) [131] that enrolled HIV infected children who 
started or were taking first line cART. The second cohort, EFV Pediatric Dose 
Optimization (EPDOS), enrolled only treatment naïve HIV-infected children newly 
diagnosed to have HIV infection. 
3.1 Patient population
As shown in Figure 4, the patient population for this PhD project included HIV 
infected children from two concurrent cohorts – EPDOS and EPHIC. In the 
EPHIC cohort, children between the ages of 3 months to 18 years who were on 
first line cART at HIV centers across southern Ethiopia were included. Children 
who were diagnosed to have virologic treatment failure and those who were on 
second line cART or were critically ill were excluded from this cohort. Similarly, 
the EPDOS cohort included cART naïve children between the ages of 3 to 16 
years who were newly diagnosed with HIV infection and starting an EFV based 
first line cART according to the WHO guidelines [45, 132]. The children in both 
cohorts were followed regularly to assess virologic outcome and cART associated 
adverse events (Figure 4). 
A total of 870 children with HIV
fromART centers in 2 regions in
Ethiopia
- HIV infected children
- On first line cART (EPHIC) OR
cART naïve (EPDOS)
- Treatment experienced
- No virologic treatment failure
cART naïve children
initiating on first-line
regimen with
ABC/AZT/TDF plus 3TC
plus EFV
Baseline pretreatment drug resistance
screening (Paper I)
HIV infected children
initiating first-line cART
followed over one year to
assess virologic outcomes
Children assessed for virological
suppression and viral rebound at
week 48 (Paper II)
Children failing first line
cART regimen assessed for
HIV drug resistance
Prevalence and correlates of HIV
drug resistance as a cause of
treatment failure assessed
(Paper III)
Metabolic and biochemical
assessments were done
among children who were
HIV infected but cART naïve
(Group 1) and those on first
line cART (Group 2)
Trend and correlates of liver and
renal toxicities among children on
cART investigated (Paper IV)
HIV and cART associated
dyslipidemia assessed (Paper V)
Figure 4. Summary of the patient population included in EPDOS and EPHIC cohorts. 
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3.2 Diagnosis and treatment of HIV Infection 
The diagnosis of HIV infection in children was made according to the WHO guidelines 
as outlined in Figure 5 [133]. For children who are older than 18 months, including 
those who were newly diagnosed in the EPDOS cohort, HIV serology testing was 
employed to confirm diagnosis of HIV infection among the study subjects. 
HIV-exposed infant or child <18 months   
Collect DBS for DNA PCR
Viral test available  Viral test not available  
Positive  Negative  
No Breast-feeding 
at all 
Breastfeeding now or 
history of breastfeeding 
Infant or Child 
likely HIV infected  
Infant or child 
is uninfected  
Infant or child remains 
at risk of acquiring 
HIV 
Regular and 
periodic clinical 
monitoring 
Immediately start 
cART and repeat viral 
test to confirm infection 
Infant remains well and reaches 9 months  
Infant or child develops signs 
and symptoms of HIV
Viral test available  
Viral test available  
Conduct HIV antibody test at 
around 9 months of age 
Negative  Positive  
Infant or child is infected  
Start cART and repeat 
DNA PCR 
Positive  
Negative  
HIV unlikely unless 
still breastfeeding 
Repeat antibody tests at 18 months of age 
and/or 6 weeks after stopping breastfeeding  
If DNA PCR not available, 
assume HIV infection if sick and 
assume uninfected if well 
Sick Well
Viral test unavailable  
a
b
Figure 5. Infant testing algorithm for children less than 18 months of age.
Source: Adapted from WHO Guidelines on antiretroviral therapy for HIV infection in infants 
and children (https://www.who.int/hiv/pub/guidelines/arv2013/annexes/WHO_CG_annex_5.
pdf) [133]. aFor newborns, test as early as possible – at or near the time of birth or at first 
postnatal visit (which is usually 4 to 6 weeks); bThere is a risk of HIV transmission until 
stopping breastfeeding.
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3.3 Patient recruitment and follow up
Children in both EPHIC and EPDOS cohorts were followed using laboratory and 
clinical parameters at predefined follow up schedule as outlined in Table 2.
Table 2. Summary of patient recruitment and follow-up for both the EPHIC and 
EPDOS cohorts
Cohort Follow up time Evaluation and assessments 
EP
H
IC
Baseline: at 
enrolment to 
cohort 
Clinical: symptom screening, TB screening, WHO clinical 
 staging, nutritional assessment, adherence assessment, 
 clinical examination
Laboratory: White blood cell, AST, ALT, CD4 count, platelet 
count, Creatinine, Blood Urea Nitrogen, Albumin, Hematocrit, 
plasma viral load, lipid profile assessment 
Follow up: 
every 6 months
Clinical: new symptoms, TB screening, WHO clinical  staging, 
nutritional assessment, adherence assessment, focused 
 clinical examination
Laboratory: White blood cell, AST, ALT, CD4 count, platelet 
count, Creatinine, Blood Urea Nitrogen, Albumin, Hematocrit, 
plasma viral load, HIV drug resistance for those who have 
first line treatment failure, and lipid profile assessment
EP
D
O
S
Baseline: at 
HIV diagnosis/
enrolment
Clinical: Symptom assessment, WHO clinical staging, 
 nutritional assessment, screening for opportunistic infections
Laboratory: Complete blood count, CD4 count, plasma viral 
load, lipid profile assessments, liver enzyme tests (AST, ALT), 
renal function tests, bilirubin, albumin and HIV drug  resistance 
testing 
Weeks 8, 12, 
24, and 48
Clinical: new symptom screening, nutritional assessment, 
TB screening, focused clinical examination, functional scoring
Laboratory: Complete blood count, CD4 count, plasma viral 
load, lipid profile tests, liver enzyme tests (AST, ALT), renal 
function tests, bilirubin, albumin 
3.4 Study procedures: laboratory and clinical 
parameters
Children were assessed at each follow up by a trained clinician on clinical signs 
and symptoms that show the control of HIV infection before and after initiation of 
treatment. The staging after treatment is referred to as t-staging (treatment staging) 
[52]. The clinical assessments included:
History and Physical Examination: detailed baseline history and physical exami-
nation with the purpose to identify any prevalent or incident opportunistic infec-
tions was done for each participant during enrolment to each cohort (EPDOS 
and EPHIC). After clinical assessment, all the participants were staged using the 
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WHO recommended clinical staging approach. The clinical stages correlate with 
the severity of the HIV infection – stage 1 indicates an asymptomatic stage while 
stage 4 indicates an advanced AIDS stage. 
WHO clinical staging: using available clinical signs and symptoms, patients would 
clinically be staged as 1, 2, 3 or 4. The clinical stages are defined based on signs 
and symptoms/ diseases described in Table 3. 
Table 3. The WHO clinical staging of HIV infection among children based on 
disease types 
WHO Stage I WHO Stage III Stage IV
Asymptomatic 
Generalized 
lymphadenopathy 
Persistent unexplained 
fever of >37.5 for more 
than 1 month 
Unexplained moderate 
malnutrition which doesn’t 
respond to standard therapy 
Persistent oral candidiasis 
beyond the neonatal period
Acute necrotizing ulcerative 
gingivitis or periodontitis 
Persistent unexplained 
diarrhea 
Oral hairy leukoplakia 
TB lymphadenopathy 
Pulmonary tuberculosis 
Anemia (<8gm/dl),  
neutropenia (<500/mm3)  
or  thrombocytopenia 
(<50,000/mm3) (unexplained) 
Lymphoid interstitial 
pneumonitis 
Severe recurrent presumed 
bacterial pneumonia 
Chronic HIV associated 
lung disease, including 
bronchiectasis
Severe malnutrition that doesn’t 
not respond to treatment 
CNS toxoplasmosis 
Pneumocystis carinii pneumonia 
Cryptococcosis, extra-pulmonary 
Cytomegalovirus of an organ other 
than liver, spleen or lymph node 
Presumed severe recurrent 
 bacterial infections
Progressive multifocal 
leuko-encephalopathy
Cryptosporidiosis associated 
chronic diarrhea 
Chronic diarrhea associated with 
isosporiasis 
Oropharyngeal or Esophageal 
candidiasis
Chronic herpes simplex virus 
infection
Disseminated endemic mycosis
Atypical mycobacteriosis
HIV associated cardiomyopathy 
or nephropathy 
Extra pulmonary tuberculosis 
except lymph nodes 
Lymphoma 
WHO Stage II
Popular itchy skin 
infections Persistent 
unexplained parotid 
gland enlargement 
Persistent  
unexplained 
hepatosplenomegaly 
Herpes zoster 
Extensive warts 
 infection the skin
Oral ulcerations 
(recurrent) 
Linear gingival 
erythema 
Recurrent or chronic 
respiratory tract 
infections 
Extensive molluscum 
contagiosum 
Fungal nail infections
Source: “Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal 
Access: Recommendations for a Public Health Approach: 2010 Revision” [134].
HIV and Treatment Related Information: HIV infection and treatment related char-
acteristics of the participants were collected at baseline and follow up as appro-
priate including if the participant was on treatment versus treatment naïve; time 
since HIV diagnosis and treatment; history related to preventive interventions like 
isoniazid preventive therapy (IPT) and cotrimoxazole preventive therapy (CPT); 
and prevention of mother-to-child transmission of HIV infection. 
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Anthropometric Assessment: weight, mid upper arm circumference, height and 
head circumference were assessed regularly. All anthropometrics were measured 
following standard procedures and using standardized/calibrated instruments. 
Anthropometric standardization was done using the WHO AnthroPlus software 
[135] and the WHO standards for categorization of anthropometrics to normal 
versus underweight. All the anthropometric z scores were categorized as under-
nutrition when the Z scores (ZS) values were < -2 whereas values >-2 ZS were 
considered normal. 
Assessment of Adherence to Treatment and Care: In the EPHIC cohort, which 
enrolled treatment experienced children and in the EPDOS cohort, which enrolled 
treatment naïve HIV infected children, adherence was regularly assessed using a 
composite of pill count, recall (24 hours and 1 week) and the visual analogue scale 
[136]. Adherence to treatment of more than 95% was considered optimal, while a 
level of less than 95% taken a sub optimal adherence to treatment. 
Assessment of Clinical Staging and New Opportunistic Infections while on Follow 
up: symptom screening was done for the children enrolled in both cohorts to assess 
the occurrence of any new opportunistic infections, assessing treatment success 
and evaluation for any evidences of treatment failure – clinical, immunological 
and virologic treatment failure were assessed. 
Assessment for Adverse Drug Reactions: adverse reactions associated with antiret-
roviral therapy were assessed using clinical and laboratory assessments. 
Clinical Assessments: These were done using structured sign and symptom check-
list. Signs and symptoms assessed included skin rash, jaundice, pallor, diarrhea or 
vomiting, dyspepsia, evidences for peripheral neuropathy, mentation and orienta-
tion or any other new symptoms during follow up. 
Laboratory Assessments: These were done to assess adverse drug reactions and 
the success or failure of antiretroviral regimens. Scheduled laboratory tests includ-
ing hematology (complete blood count – CBC, neutrophil and lymphocyte count, 
platelet count), chemistry tests (Creatinine, blood urea nitrogen (BUN), alanine 
aminotransferase (ALT), aspartate aminotransferase ( AST), lipid profile tests (low 
density lipoprotein – LDLc, density lipoprotein – HDLc, total cholesterol, high 
and triglycerides), immunology status (CD4 and CD8 count), viral load and HIV 
drug resistance testing for those who failed first line cART and those who were 
naïve to treatment before starting cART. 
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3.4.1 HIV Drug Resistance Testing
Blood Specimen Collection and Storage
We collected blood spots (~ 50 µL each) from a finger-prick of participants on 
dried blood spot (DBS) cards (Labmate, Cape Town, South Africa) and were kept 
at room temperature overnight. A sealable plastic specimen bag with adequate 
desiccants was used to store the DBS cards individually until they were shipped 
to Simon Fraser University (SFU). DBS cards stayed at room temperatures for 
about one month before shipping and were stored at −80 °C freezer once in SFU. 
Extraction and Genotyping
Nucleic acid extraction was done by transferring blood spots to sterile tubes using 
a standard 1/4” manual hole punch which was cleaned after each punch through 
punching of 10 holes into a clean paper to remove any residual material from the 
preceding participant DBS [137]. Two nucleic acid extraction attempts were made 
from each participant’s blood spots. PureLink Kit (Invitrogen, Carlsbad, CA, USA) 
was used for total nucleic acid extraction from two blood spots. Additionally, 
NucliSENSeasyMAG which is an automated system for total nucleic (BioMerieux, 
Marcy-l’Étoile, France) was used for the majority (88) of the participants.
We used PCR to amplify Protease and Reverse Transcriptase (RT) of HIV-1 contain-
ing at least codons 1-234. Amplification was done with and without initial RT step. 
A maximum of four oligonucleotide primer sets – one primary and four alternate 
primer sets which were optimized to amplify HIV-1 group M subtypes were used. 
For an initial RT step, the RT-PCR and SuperScript III One-Step RT-PCR method 
was used. Moreover, nested PCR by an Expand HiFi System (Roche) was used for 
the without initial RT amplification step. Amplicons were directly sequenced on 
DNA sequencer (Applied Biosystems, Foster City, CA, USA), 3730xl or 3130xl.
Sequencher version 5.0.1 (Gene Codes, Ann Arbor, MI, USA) was used to analyze 
chromatograms. Alternatively, automated base calling software, RECall was used 
for this purpose [138]. A quality control bioinformatics tool which is hosted by the 
Los Alamos HIV Sequence Database (LANL) (https://www.hiv.lanl.gov/content/
sequence/QC/ index.html) and the Stanford Drug Resistance Database were used 
for screening hypermutation, frame shift, deletions and stop codon. Alignment of 
sequences was done by HIVAlign (options: MAFFT, codon-alignment) [139] and 
visualization was made by AliView [140]. The maximum likelihood by PhyML was 
used for phylogenetic inference under nucleotide substation using General Time 
Reversible model [141]. To control for the effects of tree topology,  phylogenies 
were generated from full alignments and codon stripped alignments based on HIV 
drug resistance surveillance mutations [142]. FigTree (version 1.3.1) was used to 
visualize phylogenies. Patristic sequences were extracted from Newicktree files 
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using PATRISTIC which were employed to extract parasitic phylogenetically 
inferred tip to tip pairwise distances [143]. HIV LANL’s Recombinant Identification 
Program (RIP) was used to identify the HIV-1 subtype [144]. 
Drug Resistance Genotyping
The presence of drug resistance mutations which confer resistance to NRTI, 
Protease Inhibitors (PI) and NNRTI was confirmed based on Stanford 
University’s HIV Drug Resistance Database – HIVdb Program (version 8.4, https: 
//hivdb.stanford.edu/hivdb) [145, 146]. The Stanford University HIVdb program 
was also used to define individual drug resistance mutations. Genotypes having 
all degrees of reduced susceptibility to any of the drugs was defined as “resistant 
genotype” [145, 146]. Each sequence was appraised independently; moreover, 
 participants who had >1 sequence an inclusive consensus was applied. This approach 
allowed us to improve capturing the breadth of drug resistance within individual 
patients. Moreover, it helped us understand the level of underestimation of drug 
resistance testing approaches – single versus replicate [147-150]. We excluded 
hypermutated and defective sequences from the drug resistance interpretation.
3.4.2 Blood Chemistry Tests
Liver enzyme, renal function tests and case definitions
Hematology tests, immunology (CD4, CD8), hepatic enzyme and kidney function 
tests were done according to standard procedures [151]. Recommended procedures 
to ensure quality were followed and tests were done by WHO accredited labs. 
Upper limits of normal for liver enzymes - AST, ALT levels were defined at 40 
IU/L [111]; whereas, the ULN for BUN was 20 mg/dL and for serum creatinine 
was1.06 mg/dL [152].
Lipid profile assessments and definition 
We assessed the non-fasting levels of total cholesterol, HDLc, LDLc and TG 
for children enrolled in the EPDOS and EPHIC cohorts. Pediatric reference 
ranges previously published were used to define lipid profile abnormalities [124]. 
Accordingly, considering the highest value of each lipid profile parameter across 
age groups, > 200 mg/dL for total cholesterol; >150 mg/dL for triglyceride levels; 
>130 mg/dL for LDLc levels and<40 mg/dL for HDLc levels were defined as lipid 
profile level abnormalities.
Viral load assessment and clinical decision making 
Plasma viral loads were determined using quantitative PCR machine (Abbott, Des 
Plaines, IL, USA). Results were reported in copies per milliliter and retesting or 
treatment decisions were made based on the WHO and Ethiopian national HIV 
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treatment guidelines (Figure 3) [45, 132]. A plasma viral load of <150 copies per 
mL was considered the lower limit of detection and lower limit of quantification 
for the machine at a volume of 0.2 ml of plasma. Plasma viral load results were, 
therefore, reported as undetectable, <150 copies per mL (but unquantifiable) and 
quantifiable at ≥150 copies per mL. Assessment of the success of antiretroviral 
therapy and diagnosis of virologic treatment failure were done according to the 
WHO and national guidelines as depicted in Figure 6. 
Samples sent 
for viral load 
(for routine 
monitoring 
or for the study) 
VL >1000 copies/ml
Explain results
Assess adherence
Assess for intercurrent 
infections
Commence adherence 
assessment and develop 
Enhanced Adherence 
Treatment Plan
VL ≤1000 copies/ml
Explain results
Encourage continued 
adherence
Maintain current regimen
More frequent care, 
adherence monitoring, and 
support
Routine VL monitoring
Repeat VL annually
Targeted VL monitoring
Refer for management of 
clinical conditions
Continue clinical and 
immunological monitoring
VL>1000 copies/ml
Diagnose Virologic Treatment Failure
Clinician reviews case
Switch to 2nd(or 3rd if already on 2nd) 
line regimen
Adherence support and VL monitoring 
VL ≤1000 copies/ml
Explain results
Maintain current regimen
Encourage continued 
adherence
Continue routine and 
adherence support
Targeted VL monitoring 
Continue clinical and immunological 
monitoring 
Viral load if symptomatic
Routine VL monitoring
Repeat VL in 6 months and annually 
thereafter if consistently ≤1000 
copies/ml 
Figure 6. Diagnosis of virologic treatment failure and decision-making flow using viral 
load results. VL – viral load.
3.5 Statistical analysis and data management
Data were collected on paper and then entered in a database. REDCap and a dedi-
cated database developed for EPDOS were used as databases for data collection 
and data quality control [153]. Data collection was done by health professionals 
who received trainings on standard operating procedures and principles of good 
clinical practice. Data quality in both projects was ensured by regular monitoring 
and evaluation visits at the implementation sites by the researchers and trained 
supervisors. Additional quality control measures were applied in the case report-
ing formats and the databases. A weekly random assessment of filled reports was 
done on 10% of the total, which enabled taking corrective measures in the process. 
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Characteristics of study participants and baseline/follow up data were summarized 
using descriptive statistics i.e, frequency (percentage), mean (standard deviation), 
and median (interquartile range). Data were also presented in tables and figures. 
Associations with the primary end points – PDR (Paper I), rate and correlates 
of virologic suppression (Paper II), HIV drug resistance mutations as a cause 
of treatment failure (Paper III) and drug adverse events (Papers IV and V) were 
assessed using both bivariate and multivariate analysis. For normally distributed 
data, association between the outcome variables and independent categorical vari-
ables was assessed using Chi square test. Whereas, for non-normally distributed 
data, Fisher’s exact test was used to assess presence of any association between 
the outcomes of interest and categorical independent variables. To assess associa-
tions between continuous independent variables and the primary endpoint, Mann 
Whitney U test was used. 
Multivariate analysis was done to assess independent associations in Papers II to V. 
In paper II, the relationships between baseline demographic, clinical and laboratory 
variables and achieving virologic outcomes of interest were assessed using univari-
able and multivariable Cox proportional hazards regression. Kaplan-Meier survival 
analysis, with p-values computed using the log-rank test, were also undertaken to 
select baseline variables to graphically visualize relationships. The following vari-
ables were treated as binary or categorical variables, where the following reference 
categories were used. For sex, the reference category was “male”. Pretreatment 
drug resistance (PDR), tuberculosis (TB), IPT and CPT were also treated as binary 
variables (“yes” vs. “no”), where “yes” was the reference category. Categorical 
variables included cART regimen (where abacavir-based regimen was considered 
the reference category) and WHO clinical staging (where clinical stage I was the 
reference category). Hazards for continuous variables were defined as follows: – 
age (per year decrement), AST and ALT (per unit/L decrement), Albumin, BUN, 
Creatinine and bilirubin (per mg/dL decrement), baseline viral load (per log10 
copies/mL decrementCD4 count (per cells/uL increment), hematocrit (per 1% 
increment), and total cholesterol, LDL, HDL, TG, WAZ, HAZ and BAZ (per mg/
dL increment). In survival analyses, subjects who were lost to follow up or who 
died were censored at their last follow up timepoint. Covariates with a p-value of 
<0.2 in univariable analyses were included in the multivariable models.
In Paper V, binary logistic regression was employed to determine association 
between independent variables – decrease by 1 year of child’s age, decrease by 
1mg/dL of the hemoglobin level, being clinical stage 3/4 disease, a decrease by 
1 Z-score of weight-for-age and height-for-age z score (WAZ and HAZ) were 
included in the final multivariable regression model as these had a p-value <0.2 
in the univariable model. 
Finally, in the multivariate models, p value of <0.05 was set as the level of statisti-
cal significance. R software package was used for the analysis. 
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3.6 Ethical considerations
Ethical approvals were obtained from the SNNPR Regional Health Bureau 
(RHB) Institutional Review Board (IRB), Addis Ababa University, College of 
Health Sciences IRB, Karolinska Institutet and the National Research and Ethics 
Review Committee (NRERC) of Ethiopia (Reference numbers: 3-10/46/2018, 
21 March 2018 for the EPHIC cohort and SHE/SM/14.3/0421/1/2019 (renewal) 
for the EPDOS cohort). Parents/guardians of participating children gave written 
informed consent, while children <12 years gave assent additionally. All data 
collection forms were made anonymous to ensure confidentiality and stored in 
secure locations accessed by only limited personnel. Participation was completely 
on voluntary basis and participants were informed that they were free to withdraw 
from the studies at any time without any consequences.
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4 RESULTS AND DISCUSSION
A total of 870 study participants were enrolled in two cohorts – EPHIC and EPDOS 
from January 2016 to January 2019. From these, 111 (12.8%) were newly diag-
nosed HIV infected children who were treatment naïve from the EPDOS cohort, 
while the rest 769 children were on first line cART from the EPHIC cohort [131]. 
Children enrolled from EPDOS cohort were followed for 48weeks, while those 
from EPHIC for 18 months.
Children in the EPDOS cohort who were assessed for baseline pretreatment HIV 
drug resistance (Paper I) were prospectively followed to assess virological out-
comes (Paper II). Among children who failed first line combination antiretroviral 
therapy, HIV drug resistance was assessed as a cause of the failure (Paper III). 
Children who have been on cART were also prospectively followed for renal and 
hepatic toxicities (Paper IV). We also assessed for and compared HIV infected 
cART naïve children from the EPDOS cohort with cART experienced HIV infected 
children from the EPHIC cohort for metabolic derangements (Paper V). Paper I 
assessed the burden of pretreatment HIV drug resistance while paper II assessed 
virologic outcomes including virologic suppression and rebound during the first 
year of cART in a cohort of children followed for 48 weeks (Figure 1 or Paper II). 
It also explored the predictors and trend of virologic response during the first year 
of treatment included pretreatment drug resistance using the data from Paper I. 
Children in the EPHIC cohort were assessed for virological treatment failure 
at enrollment. A total of 94 children who had virological treatment failure and 
had a viral load of >2500 copies per mL underwent HIV drug resistance testing 
(Paper III). The rest with no treatment failure were followed for 18 months to 
assess renal and hepatic drug adverse events (Paper IV) and a subset of children 
underwent screening for dyslipidemia (Paper V).
4.1 Pretreatment HIV Drug Resistance among HIV 
infected Children (paper I)
A total of 93 children with a median age of 9 years (Interquartile range (IQR): 
5-12) were included in the analysis for paper I. The children had a median CD4+ 
T-lymphocyte cell (T-cell) count of 319 (IQR: 141-615) cells/mm3 and median 
viral load of 4.3 log10 copies/mL (IQR: 3.7-4.9 log10 copies/mL).
Prevalence of PDR and Drug Resistance Mutation Types
From all the 93 participants, we collected DBS; N=22 or Dried Plasma Spots 
(DPS; N=71). Genotyping for HIV drug resistance succeeded for 57/93 (61.3%) 
of the samples, which is comparable to reports which used dried blood products 
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for genotyping [154-156]. Furthermore, success rates did not significantly differ 
between DPS (14 of 22; 63.6%) and DBS (43 of 71; 60.6%) (p=1.0) specimens. 
Additionally, genotyping success rate was similar across all patient characteristic 
which are described in Table 2, except the weight-for-age Z-score where children 
with successful genotyping had median Z-score of -1.9 (IQR -2.9-(-0.9) compared 
to -1 (IQR -1.7-(-0.1)) for those in whom genotyping was unsuccessful (p=0.03).
Consistent with the reported national HIV epidemic which Ethiopia experienced 
with subtype C [157-162], 54/57(94.7%) children had HIV subtype C, 1/57(1.7%) 
each of AG recombinant type, ACG recombinant and A subtypes were identified 
in the included children (Figure-1 of Paper I). No phylogenetically-linked infec-
tions were found except a pair of siblings who had closely clustering sequences. 
This finding is consistent with most pediatric cohorts.
From those participants who were successfully genotyped, 8/57 (14%) HIV DRMs 
(Figure 1 of Paper I). All 8 children with PDR harbored resistance to NNRTIs – 
5(62.5%) had NNRTI DRMs only while 3(37.5%) were found to have dual class 
resistance. PI drug resistance mutations were not observed in any of the participants. 
Five of 43 and 3/14 children from DBS and DBS groups respectively harbored 
HIV drug resistance mutations, indicating that there are no significant differences 
in the level of PDR between the groups (p = 0.4). 
Table 3 of Paper I depicts the DRM profiles among the included participants. 
Overall, G190A and Y181C were the most common NNRTI drug resistance muta-
tions. Moreover, K103S, K103N and Y188L were identified in one participant each. 
L210W, M184V, M184I, T215Y and K219N were observed NRTI drug resistance 
mutations. EPDOS_8 and EPDOS_53 (GeneBank) harbored HIV drug resistance 
observed in more than one drug class. 
Associated Factors with Pretreatment HIV Drug Resistance 
We next sought to explore the correlates occurrence of PDR among (Table 4 of 
Paper I). Drug resistance as an outcome was categorized as yes or no for the pur-
pose of this analysis. Children who harbored PDR were younger that those without, 
but the association did not reach statistical significance (median 5 [IQR 0.3-10] 
versus 8 [5-12]) (p=0.06). Furthermore, lower albumin level predicted PDR even 
though there was only a modest reduction (2.9 IQR: 2.5-3.4 mg/dL among children 
harboring resistance versus 3.8 3.2-4.2 mg/dL among those without; p=0.04). Low 
albumin levels could implicate undernutrition as a consequence of drug resistance 
causing poor treatment outcomes; however, children with and without PDR did 
not have statistically significant differences in their anthropometric. It is known 
that albumin is one of most abundant proteins in human blood plasma and plays 
role in drug transport and metabolism [163, 164]. However, mechanism of the 
link between lower albumin level and presence of PDR in the current cART-naive 
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pediatric population, and the potential clinical implications of the link, are currently 
not clear and require confirmation in larger, independent studies. 
None of the clinical and laboratory variables assessed predicted PDR. Only 
three children exhibited resistance to NRTIs as part of a dual class resistance 
which  limited the plan to assess correlates of resistance in this group of patients. 
Participants who exhibited NNRTI/NRTI dual class PDR were younger than those 
who had single or no drug class resistance (0.2 [0.1-0.3] versus 8 [5-12]) (p=0.02).
These figures of PDR among HIV infected newly diagnosed Ethiopian children 
represent a substantially higher burden of PDR in this population than newly diag-
nosed HIV infected adults where the rate of PDR was around 3.9% [104]. Reports 
on the burden of PDR among adults and children from other similar settings with 
high HIV prevalence support our findings from Ethiopia on the rate and predictors 
of pretreatment drug resistance among both adults and children [165]. PMTCT 
exposure in children could explain the relatively higher prevalence of PDR among 
children as compared to adults [166]. 
Reports show that the prevalence of PDR within several sub-Saharan African 
countries is increasing over the past two decades. In some settings, the increment 
occurred at alarming levels [100, 167]. The observations in this analysis further 
underscore the concern that HIVDR could be a major threat to the HIV epidemic 
control efforts in resource-constrained settings [168] and identify the pediatric 
population particularly to be at risk of poor treatment outcomes owing to the high 
HIV PDR levels. In settings where the NNRTI pretreatment resistance exceeds 
10%, the current WHO treatment guidelines recommend against using NNRTI-
containing regimens as first-line treatment [169]. Based on WHO guidelines, for 
children >3 years of age, the recommended first line regimes contain a combina-
tion of two NRTI drugs (3TC with one of ABC, TDF, or AZT) and one NNRTI 
drug (either EFV or NVP) while second line regimens include two NRTI drugs 
(3TC and one other NRTI which was not part of the failing first line regimen) 
plus PI [41, 42, 45, 170]. 
4.2 HIV treatment outcomes amomg hiv infected 
children (Paper II)
Baseline characteristics of the children who were enrolled for this sub study are 
described in table 1 of paper II. Briefly, a total of 111 cART naïve HIV infected 
children were initially enrolled in the EPDOS cohort [171]. However, follow-up 
was limited to the 110 (99.1%) children as one child did not participate in the 
baseline and follow up assessments. During the study period, a total of 16  children 
did not complete follow up –13 children (11.8%) were either lost to follow up 
or were transferred out to another center out of the study catchment region and 
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three children died: a 13 year boy died at home of unknown cause, and two girls, 
aged 6 and 10 years, who had initially lost to follow up, were later confirmed to 
have died when the study team attempted to trace them (Figure 1 in Paper II). In 
total, 97 (88.2%) participants successfully completed all 48 weeks of follow-up. 
Of the 110 HIV infected treatment naïve children who entered follow-up, 94/110 
(85.5%) achieved undetectable viremia, defined as pVL<150 copies per mL, at 
some point during the study period. The level of virological suppression rate in this 
study is comparable to reports by other studies [71, 172-174].The finding gives 
an important insight in towards the progress in the global targets in Ethiopia. In 
Ethiopia, there is no disaggregated countrywide pediatric data on the rate of sus-
tained virological suppression among HIV infected children who initiated cART 
(that is, the statistic represented by the third “90” of the UNAIDS 90-90-90 goal) 
[175]. Only a collective estimate of 86% virological suppression has been reported 
in 2016, which is higher than the ESA regional average of 52% [41, 176, 177]. 
We further explored clinical and laboratory associates of virological suppression 
to pVL<150, using Cox proportional Hazards regression. In bivariate analyses, 
several variables were weakly associated with attaining undetectable viremia at 
p-values <0.2. Each decrease of one integer unit of body mass index for age Z-score 
(BAZ) was associated with a 10% higher hazard of achieving undetectable viremia 
(Hazard Ratio(HR) 1.1 [95%CI 0.9-1.3], (p=09). Being on a TDF-containing cART 
regimen was associated with a 40% increased chance of achieving undetectable 
viremia (HR 1.4 [95% CI 0.9-2.1] compared to participants on other regimen types 
(p=0.18). The relationship between virological suppression to undetectable levels 
and NRTI drug type contained in first line cART is also depicted using Kaplan-
Meier curves in Figure 2. Moreover, lacking pre-treatment drug resistance (PDR) 
was associated with a 2.1-fold increased hazard of achieving undetectable viremia 
(Hazard Ratio 2.1 [95% CI 0.7-5.9]) compared to participants with PDR (p=0.16). 
The relationship between PDR and time to achieving pVL<150 copies/ml is also 
graphically illustrated in Figure 2. On the other hand, not taking isoniazid preven-
tive therapy (IPT) was associated with 30% decreased hazard of achieving viro-
logical suppression (HR 0.7 [95% CI 0.5-1.2], p=19). Similarly, being classified 
into WHO clinical stage 2 or stage 3 was associated with 30% decreased hazard of 
achieving undetectable viremia (HR 0.8 - [95% CI 0.7-1.1]) as compared to being 
classified into stage 1 (p=0.08, data not shown). Each decrease in baseline viral 
load by one log10 copies per ml was associated with a 20% decreased hazard of 
achieving undetectable viremia (HR 0.8 - [95%CI 0.7-1.1]) (p=0.13). Virological 
suppression to undetectable levels stratified by baseline viral load is graphically 
illustrated using Kaplan-Meier curves in Figure 2. Each decrease in baseline low 
density lipoprotein (LDL) by one mg/dl was associated with a 10% decreased 
hazard of achieving undetectable viremia (HR 0.9 - [95% CI 0.9-1.0], p=0.17). 
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A multivariable model was constructed using all baseline parameters with p-values 
of <0.2 in the univariable analyses, with the exception of body-mass-index-for-age 
Z-score (BAZ). The latter was excluded to avoid the possibility of collinearity, 
as both height-for-age Z-score (HAZ) and weight-for-age Z-score (WAZ) were 
included in the model, and BAZ is a function of weight and height. After adjust-
ment for all baseline factors included in the model, the only variables that remained 
independently associated with virological suppression <150 copies per mL were 
pretreatment drug resistance and type of cART regimen (Table 2). Lacking pre-
treatment HIV drug resistance was associated with an 11 times higher chance of 
virologic suppression to undetectable levels compared to having PDR (HR: 11.1 
95% CI: 1.3–94.7, p-value= 0.028). Being on a TDF based cART regimen was 
associated with 3.1 times higher chance of virological suppression compared to 
being on an ABC based regimen (HR: 3.1; 95%CI: 1.0-9.6; p-value=0.049).
The impact of PDR on virologic outcomes among newly-diagnosed HIV infected 
children is not well established in resource-limited settings [82, 104, 178-180]. In 
theory, PDR could compromise the efficacy of first line cART regimens, thereby 
reducing rates of virological suppression and increasing subsequent rates of viro-
logical treatment failure. However, previous studied have reported conflicting 
results. Several African and multinational studies reported a positive association 
between PDR and virologic suppression, while other studies reported the lack of 
any association between PDR and virological suppression [82, 181]. Our study 
showed that presence of any PDR was associated with reduced rates of virological 
suppression, after adjusting for other baseline factors. 
The difference in virological suppression between HIV infected children with 
PDR and those without is significant after the third month of cART indicating that 
more children with PDR continue to have high viral load. Interestingly our result 
indicates no significant association of PDR with risk of viral rebound. Despite 
several studies which reported the relevance of baseline viral load as a predictor 
of virologic outcome [182-184], our study demonstrated no association between 
the level of baseline viral load and virologic response. 
Antiretroviral regimens types have different safety and efficacy outcomes among 
children with HIV infection. All the children who were included in the current 
cohort were started on an EFV based cART regimen based on the WHO 2016 
consolidated guideline [52], which limited our ability to compare the impact of 
NNRTI drug types on virological outcomes. A tenofovir based regimen was found 
to be associated with better virological suppression compared to an abacavir 
based cART regimen. However, studies have shown comparable antiviral activity 
between tenofovir/lamivudine and abacavir/lamivudine combined with dolutegravir 
and abacavir/lamivudine versus tenofovir/ emtricitabine [185-187]. The similar 
findings in previous reports could be because of using different third agent in the 
cART combination and warrants more investigation.
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We next assessed rates of virologic rebound our cohort. We defined virologic 
rebound as registering at least one pVL ≥ 150 copies/mL after having first achieved 
a pVL of <150 copies/mL; as such, this analysis was limited to the 94 children 
who had achieved virological suppression at least once during follow up. Of these 
94 children, 36 (31.9%) subsequently experienced virological rebound. Specifically, 
of these 36 children, 11 (30.6%), who were suppressed at week 8 had a rebound 
at week 12; another 11 children (30.6%) who had achieved suppression at weeks 
8 and/or 12 had rebound at week 24; and, 14 (38.9%) children who had achieved 
one or more virological suppression at weeks 8, 12 and/or 24 had viral rebound 
at week 48. 
We next employed Cox proportional Hazards regression to characterize the rela-
tionship between participant clinical and sociodemographic characteristics and risk 
of virologic rebound. Of note, the variables investigated in the present analysis 
were those measured at baseline, not at the time of initial virologic suppression. 
On univariable analysis, a decrease by one year of age was associated with a 10% 
lower risk of viral rebound (HR 0.9 - [95% CI 0.8-1.0], p=0.12). Similarly, taking 
a TDF-containing first line regimen resulted in a 60% reduction in the hazard of 
virologcal rebound (HR 0.4 - [95% CI 0.2-0.9], p=0.027).The trend of virological 
rebound stratified by the NRTI drug contained in first line regimen is depicted 
using Kaplan-Meier curves (Figure 3 in Paper II). Not taking CPT was also asso-
ciated with a 60% reduction in the hazard of virological rebound (HR 0.4 - [95% 
CI 0.2-0.9], p=0.04). On the other hand, being WHO clinical stage 4 increased the 
hazard of virological suppression by 4-fold (HR 4.0 - [95% CI 1.1-14.3], p=0.036). 
The relationship between CPT status and WHO clinical stage with the trend of 
virological rebound is described using Kaplan-Meier curves in Figure 3. Not tak-
ing IPT also increased the risk of virological rebound by 1.7-fold (HR 1.7 - [95% 
CI 0.8-3.6], p=0.18) (Table 3 in Paper II). 
Multivariable cox proportional hazards model was constructed using all the vari-
ables with p-value <0.2. After controlling for confounders, all the covariates did 
not reach statistical significance expect WHO clinical stage which showed a weak 
association. Specifically, being classified as WHO clinical stage 4 disease resulted 
in a 3.6 times increased hazard of virologic rebound (HR 3.6 - [95% CI 0.7-18.8], 
p=0.13) (Table 3). 
Of note, of the 36 children who experienced viral rebound following initial 
 suppression according to the above definition, 30 (83.3%) registered only a single 
pVL result ≥ 150 copies per mL after which they later re-achieved virological sup-
pression to < 150 copies/ml. The remaining 6 children (16.7%) never re-achieved 
suppression, and fulfilled the WHO definition of virological treatment failure 
(VTF), defined as two successive pVL results ≥1000 copies per mL, recorded at 
least 3 months apart, after at least 6 months on cART [52] . Indeed, 9 of the origi-
nal 110 study participants (8.2%) had fulfilled the definition of VTF according 
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to the WHO guidelines: these included the latter 6 participants as well as three 
additional children who never achieved pVL suppression < 150 copies/ml at any 
point during study follow up.
Even though a high proportion of children initially achieved virological suppres-
sion, almost one-third (31.9%) proportion subsequently registered at least one 
pVL ≥ 150 copies per mL, a rate that is similar to a study from South Africa [177]. 
Those who were classified as being WHO clinical stage 4 had an increased hazard 
of virologic rebound. Promisingly however, the majority (~80%) of participants 
who experienced viral rebound went on to re-achieve pVL suppression, suggesting 
that most were transient viral “blips” rather than an indication of virologic treat-
ment failure (VTF). Indeed, VTF rates were relatively low: only 9 of the original 
110 study participants (8.2%) fulfilled the WHO definition of VTF at the end of 
the study period. Taken together, the findings show that newly diagnosed HIV 
infected children who are started on standard cART regimes, as recommended by 
the WHO guidelines [52], generally do well virologically at 48 weeks of treatment. 
4.3 Prevalence and Correlates of Acquired HIV Drug 
Resistance (Paper III)
In paper III, we evaluated the rate of HIV drug resistance among treatment expe-
rienced HIV infected children who failed first line cART. Resistance analysis was 
done based on inclusive consensus sequence which was assembled from all existing 
intact HIV-1 sequences every participant to avoid the possibility of underestimating 
the degree of in individual children (Figure 1A of Paper III)[147-150, 188-191]. 
A high prevalence of HIVDR was recorded – for 73/90 (81%) at least one drug 
resistance mutation was recorded (Figure 1B of Paper IV). The most common form 
of resistance was dual class resistance where 62 (69%) children had resistance to 
both of NRTI and NNRTI. Only one child had resistance to three drug classes – 
PI, NRTI and NNRTI. Nine (10%) children had resistance to NNRTI while one 
child had isolated resistance to NRTIs (1%). In 17 (19%) of the children, no drug 
resistance mutations (DRMs) were observed which indicates towards the signifi-
cance of other factors for treatment failure. 
A broad range of DRMs were observed among participants who harbored drug 
resistance mutations. Forty-five NRTI DRMs which are described in the Stanford 
database were used to interpret our results [146, 192]. We also referred to the 
IAS-USA list while interpreting our findings [193]. Twenty-eight of the 45 (which 
occurred at 15 codons) were observed during this analysis. M184V was the most 
frequent NRTI DRM, 61/64 (95%) of children with NRTI DRM, which is consist-
ent with the rapid selection by 3TC (Figure 2A of Paper IV) [194-197]. The next 
most frequent DRMs were those for AZT and d4T; namely, T215Y, D67N, K70R, 
M41L, and L210W [146]. Each of these were recorded in 23%, 25%, 22%, 20% 
and 20% of children with NRTI resistance, respectively. 
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Thirty six of the NNRTI DRMs which occurred at 18 RT codons are defined [146, 
192, 193]; from these, 25 which occur at 17 codons, were recorded among the 
children in our study. Y181C DRM which is known to confer resistance to all of 
the NNRTIs, and K103N DRM which is attributed to high-level resistance to EFV 
and NVP, were recorded in about a third of the participants with NNRTI resistance, 
respectively (Figure 2B of Paper IV) [146, 198]. Moreover, K101E and G190A 
which cause resistance to NVP and EFV [146], were recorded among 17% (13/72) 
and 28% (20/72) of participates with NNRTI resistance, respectively. Overall, our 
results show the diverse drug resistance mutation profiles among HIV-1-infected 
children who experience virologic first-line treatment failure. The findings broadly 
reflect the specific antiretrovirals used as first-line drugs in the region, with their 
relative mutational barriers [146, 194-198].
Impact of the findings for first and second line WHO-recommended regimens in 
the region
According to WHO and national guidelines, Ethiopia currently recommends two 
NRTIs (3TC plus one of AZT or ABC or TDF) with one NNRTI (one of NVP or 
EFV) as first-line treatment for children three years and older [132, 170]. Further, 
two NRTIs (3TC and one other NRTI not included in the failing regimen) and 
a PI constitute a preferred second line regimen [132]. All the participants with 
NNRTI resistance had resistance for both NVP and EFV which is consistent with 
high levels of cross-resistance in the NNRTI group (Figure 3A of Paper III)[198]. 
This finding leaves the PIs as the main second-line options in such settings which 
is in-line with the available guidelines. However, the implications of the NRTI 
resistance profile are more worrisome indicating that the second line regimes might 
not be as effective. Specifically, 62/64 (97%) participants exhibited resistance to 
3TC (including ABC and Emtricitabine [FTC]) because of the M184I/V mutation 
 carriage (Figure 3A of Paper IV). This finding indicates that the inclusion of 3TC in 
second line regimens will compromise the efficacy of the regimens. Furthermore, 
45% (29/64) and 53% (34/64) children who had NRTI resistance mutation confer 
resistance to TDF and AZT, respectively. Our findings show that resistance muta-
tions which conferred resistance to two of the NRTIs which are recommended for 
use in first- and second-line cART regimens by WHO and National Guidelines in 
Ethiopia were observed in 27/64 (42%) of the participants. Nine children (13%, 
9/64) had resistance to three of the NRTI drugs while 42% (27/64) had resistance 
mutation to all four (Figure 3B of Paper IV) [132, 170]. In summary, the success 
of recommended second-line regimens could be significantly compromised due to 
the high burden of HIV drug resistance observed in this study. This is especially 
worrying as there are no third line options for children in Ethiopia [132], and more 
importantly, in sub-Saharan Africa, access to alternative treatment regimens is 
significantly limited [199, 200].
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Predictors of drug resistance among HIV infected children failing first line treatment 
Finally, we explored factors that are associated with drug resistance as shown in 
Table 2 of Paper IV. Longer duration of cART was associated with more resist-
ance to NNRTI resistance (median 50.5 [IQR 23-72 months] versus 20.5 [6.4-
46.5] months, p=0.02). The same trend was observed for NRTI resistance and any 
resistance. Drug substitution predicted a higher probability of NRTI mutation (57% 
among those who underwent drug substitution versus 30%among those without, 
p=0.04), a trend that was also observed among participants with any resistance 
and NNRTI resistance. On the other hand, EFV containing regimens exhibited a 
significantly less common resistance: 47% of children with no resistance were 
taking EFV-containing regimens as opposed to only 21% of children with any 
resistance, p=0.03. This observation is in line with the higher antiviral activity 
of EFV than NVP containing regimen [201, 202]. The findings show that closer 
follow up is warranted for children who have been on treatment longer and those 
who underwent drug substitution. Additionally, NNRTI regimens which contain 
EFV might be protective against drug resistance-associated virologic failure.
4.4 Liver and renal toxicities associated with long term 
cart use (paper IV)
For the analysis in this sub study, we used a total of 705 children, from the EPHIC 
cohort, who had serial measurement of markers of liver and kidney damage. The 
children included those who had at least one hepatic enzyme and renal function 
tests performed during the follow up period. At enrolment, 6, 12 and 18 month 
follow up, data were available for 705, 615, 554 and 490 children, respectively. 
All four tests done for a total of 450 children. The children were a median age of 
12 years (Q1-Q3: 8-14 years); more than half (53.3%) were male. Participants 
were a median of 3.3 years (Q1-Q3: 1.1 – 6.1 years) on first line cART and 
were on different regimens at enrolment including AZT,3TC,NVP 343(44.1%); 
D4T,3TC,NVP 162 (20.8%); AZT,3TC,EFV 109(14.0%); TDF,3TC,EFV or NVP 
74(9.5%), D4T,3TC,EFV 45(5.3%); ABC,3TC, EFV or NVP or Lopinavir/ritona-
vir, 41(5.3%) and AZT or D4T,3TC,Lopinavir/ritonavir 3(0.39%). 
Liver enzyme abnormalities among children taking first line antiretroviral therapy 
A quarter of the children 177(25.1%) had elevated AST, while a tenth 83(11.8%) 
exhibited high ALT levels. Younger age at enrolment was associated with elevation 
of AST levels (p=0.008), being NVP or AZT based cART regimens (p=0.001), 
shorter time on cART (p=0.02) and a pVL>1000 copies/mL (p=0.03) (Table 1 of 
Paper IV). Shorter treatment duration was associated with increased risk of  having 
abnormal AST levels 6 months into enrolment (p=0.03) (Table 2 of Paper IV). 
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Similarly, for ALT levels, young age (p=0.003), shorter duration of treatment 
(p=0.03) and having pVL>1000 copies/mL (p=0.03) predicted abnormal levels 
(Table 1 in Paper IV). 
Further, we assessed the trend of liver enzyme abnormalities over the duration of 
the follow up period (Figure 1 of Paper II). We used linear mixed model regres-
sion to investigate the trend of AST abnormalities. Ove the follow up period, 
an estimate of 1.4 (95% CI: 0.4-2.5) IU/L per each follow-up time (p= 0.01). 
Similarly, the ALT decreased by 1.4 (95% CI: 0.2-2.6) IU/L at each follow-up 
visit (p =0.01). However, the trend of the change in AST and ALT stratified by the 
cART regimen did not reach statistical significance except for those taking a NVP 
containing first-line regimen where those taking NVP containing regimen had a 
significantly higher change than those taking EFV based regimen (p-value=0.04) 
(Figure 2 and Figure 3 in Paper II).
Our findings in this analysis are in line with results reported by other studies in 
different settings. For instance, a four year follow up study found similar findings 
with regards to the pattern of liver enzyme changes [203]. The decreasing pattern 
in the level of liver enzymes could be interpreted differently. It could indicate 
stabilization of the liver damage in the earlier phases of cART initiation. On the 
other end, it could also signal a deteriorating liver damage where signs of liver 
failure could also manifest. Ultrasonography and liver synthetic tests could help 
conclusively determine if this trend suggests deteriorating liver function [204]. 
In order to assess if liver enzyme abnormalities observed in the study suggest 
progressive normalization or deterioration, we further assessed the burden of 
liver fibrosis using noninvasive markers – the APRI score and FIB-4 index. From 
those screened, a total of 76(10.2%) at enrolment, 56(9.6%) at 6 months, 29(9.6%) 
at 12 months and 18(6.3%) at 18 months had a score of >0.5, which suggests 
liver fibrosis(p=0.03). Moreover, based on the FIB-4 index, 8(1.2%) at enrol-
ment, 3(0.6%) at 6 months, 3(0.9%) at 12 months and 0 at 18 months had FIB-4 
index>1.5which also suggests fibrosis (p=0.05). An APRI score of >1.5 suggests 
cirrhosis – from the EPHIC cohort, 9(0.9%), 5(0.8%), 3(0.8%), and 1(0.3%) had 
levels suggesting cirrhosis at respective follow up times of 6, 12 and 18 months. 
There was a statistically significant reduction in the APRI score over the course 
of the follow up – a reduction of 0.02 units per follow-up visit was recorded (95% 
CI: -0.04 – (-0.006)) (p=0.01). However, the reduction in the FIB-4 score was 
not statistically significant (p=0.44). These findings support the possibility that 
normalization of the liver enzymes could likely be an indication of stabilization 
following cART initiation, where there could be acute liver toxicity associated 
with some of the antiretroviral regimen drugs. 
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Abnormalities in renal function tests among HIV-infected children taking first 
line cART 
To assess renal function of the enrolled HIV infected children, we assessed creatinine 
and BUN. In most of the analysis, GFR was used instead of creatinine clearance 
since creatinine value would vary by age, height and weight [205]. Reassuringly, 
baseline derangement in renal function were less common in the studied cohort. 
Elevated creatinine (above upper limit of normal for age) was observed in 24(3.4%) 
and while 84(12.1%) had elevated BUN levels. Elevated BUN level at enrolment 
was significantly more common among young children. Only six children had a 
mild reduction in GFR (60-90 mL/min per 1.73 m2) (Table 1 of Paper IV). There 
was a significant increment of the BUN level during the course of the follow up. 
However, the worrying finding in this analysis was that there was a significant 
increment in BUN and a significant decrement in GFR. Specifically, the BUN 
increased by a median of 1.6(95% CI: 0.4-2.7) mg/dL for every 6 month increase 
in treatment duration (p=0.01) and the GFR decreased by 35.6 (95% CI: 17.7-
53.4) mL/min per 1.73 m2 (p-value <0.0001) for every 6 month follow up (Figure 
1 of Paper II). Of note, cART regimen type was not associated with the change in 
both BUN and GFR (Figure 2 and 3 in Paper II).This finding is in contrast to other 
studies which reported that TD-containing regimens increase the risk of renal func-
tion derangements for example an increased risk of persistent renal disease (PRD) 
[206-209]. However, we noted a difference in the median GFR between cART 
regimen types – children who were taking D4T and TDF -containing regimens 
had lower GFR than the other groups. Likely because of the small sample size in 
the sub groups particularly those taking a TDF-containing first line regimen, the 
differences did not reach statistical significance. 
The trend of the GFR showed a down-hill pattern which could indicate a progres-
sive renal disease. Similar findings were reported using serum creatinine levels in 
a four years follow up among a small group of HIV infected children and adole-
scents [203]. The progressive increment in BUN and decrement in GFR both 
 warrant a closer follow up for an earlier systematic prevention and management of 
the renal complications of effects of cART or the HIV infection – HIV  associated 
nephropathy (HIVAN) [210]. 
4.5 Metabolic drangements among HIV infected 
 children on treatment (paper V)
Data of 320 children from the EPHIC and EPDOS cohorts, with median age of 
11.0 (Q1-Q3: 7.01 – 14.0) years were used for this analysis. Nearly half, 165 (49 %) 
of the children were male. From the total, 105 (32.8%) were treatment naïve HIV 
infected participants (Group 1) while 215 (67.2%) participants were taking first-line 
treatment (Group 2), who were taking D4T, 3TC, NVP – 54(23.5%); AZT, 3TC, 
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EFV – 27(11.7%); AZT, 3TC, NVP – 90(39.1%); D4T, 3TC, EFV – 12(5.2%); TDF, 
3TC, NVP or EFV – 15(6.5%) and ABC, 3TC with EFV, NVP or PI – 4(1.7%). 
The median duration on cART was 54.0(Q1-Q3: 23.0 – 86.5) months. 
From the children in Group 1, 41(39.0%) were WHO clinical stage 1 – 23(21.9%); 
WHO clinical stage 2 – 31(29.5%); WHO clinical stage 3, and 9 (8.6%) WHO 
clinical stage 4.Whereas, from Group 2, 35(16.0%), 61(25.6%), 77(33.5%) and 
11(5.5%) were WHO clinical stage 1, 2, 3 and 4, respectively. Irrespective of treat-
ment status, more children from Group 2 had a WHO clinical stage 3 or 4 disease 
compared to Group 1 (p=0.04). 
Group 1 children were younger than children in Group 2 (p< 0.001). Children taking 
antiretroviral therapy had better immunologic recovery evidenced by significantly 
higher median CD4 count and virological suppression (p<0.001) as compared to 
those who were cART naïve. Similarly, anthropometric indices were better among 
Group 2 children than Group 1 (Table 1 of Paper V). 
Dyslipidemia among HIV infected children by treatment status
We compared Group 1 and 2 children for dyslipidemia. Median total cholesterol in 
Group 1 was higher than those in Group 2 (median=120.0 mg/dL, IQR: 97.8 mg/
dL – 150.0 mg/dL as compared to median=102.5 mg/dL, IQR: 80.0 mg/dL – 127.8 
mg/dL, respectively; p=0.001). Conversely, HDLc was lower among Group 2 than 
in Group 1 (median=45.0 mg/dL, IQR: 30.3 mg/dL – 48.0 mg/dL and median=48.5 
mg/dL, IQR: 41.0 mg/dL – 66.9 mg/dL, respectively) (p=0.002). 
We then dichotomized lipid parameters in to normal and dyslipidemia based on the 
suggested lower and upper limits of normal. More children from Group 2 (40.2%) 
compared to those from Group 1 (23.4%) had abnormal HDLc levels (p=0.006). 
Triglyceride level was also higher among Group 2 than Group 1 even though not 
statistically significant (p=0.16). Overall, any lipid profile abnormality was more 
common among children in Group 2 (70.2%) than in Group 1 (58.1%) ( p=0.033) 
(Table 2 of Paper V).
Whilst lingering medical conditions including obesity and HIV infection are pos-
sibly linked to dyslipidemia, normal children with normal anthropometrics from 
the sub Saharan African region demonstrate a very low burden of dyslipidemia 
[211]. Previous reports documented a high burden of dyslipidemia associated with 
HIV infections – findings which are in line with the our analysis [128, 212-214]. 
Similar the trend observed in our analysis, studies from India, which included HIV 
infected children with and without treatment experience, similarly high prevalence 
of hypertriglyceridemia and low HDLc levels [213] [214]. Moreover, a study in 
Uganda among treatment experienced HIV-infected children reported similar 
dyslipidemia profile [212]. Treatment status as a risk for dyslipidemia was also 
similarly reported among a cohort of adult HIV infected patients in Ethiopia [215]. 
36
In this analysis (Paper V), presence of treatment experience was associated with 
lower total cholesterol values possibly indicating differential lipid type abnormali-
ties with treatment experience, for example abnormalities in hypertriglyceridemia 
and low HDLc levels were more common among children in Group 2. As there 
are limited data investigating the pattern of dyslipidemia stratified by HIV infec-
tion status, more data on the specific types of dyslipidemia and correlates would 
shade light on the detailed burden of the problem for possible preventive and 
therapeutic action. 
Even in the absence of HIV infection, undernutrition and obesity are linked to 
dyslipidemia [216-218]. Our analysis demonstrated that undernutrition was related 
to risk of dyslipidemia within Group 1 children, while there was no significant 
association among children in Group 2. The beneficial effects of treatment leading 
to improvements in anthropometrics which was the case for children who received 
treatment for at least six months could explain this finding. 
The finding of more dyslipidemia among children with treatment experience and 
duration on treatment compared to cART naïve children warrants a special attention 
as these children need to be followed with regular biochemical assessments. With 
the introduction of efficacious cART, the life expectancy of HIV infected children 
in resource limited settings is expected to increase, which necessitates minimizing 
long and short-term adverse reactions as an important component of the care and 
treatment package. In HIV infected children, cardiovascular risks (CVD) have been 
linked to persistence of dyslipidemia [219, 220]. CVD could possibly threaten the 
accomplishments gained in cutting child mortality and morbidity associated with 
HIV infection [221]. Even though these complications are less common and a 
relatively smaller group of children would require therapeutic interventions, risk 
of CVD could be minimized through integration of routine screening in the HIV 
care and treatment package, practicing recommended modifications in life style 
and lipid lowering interventions, when needed [222]. 
The deleterious consequences of persistent dyslipidemia in children were investi-
gated [223]. Our findings in this analysis add to the existing body of literature on 
the risk posed by persistent dyslipidemia including neurologic and cardiovascular 
accidents in the absence of treatments which need to be administered to lower the 
lipid level in the early stages of abnormality. Treatment experience was shown 
to be an important predictor of dyslipidemia among children with HIV infection. 
These findings emphasize the demand for a targeted follow up with emphasis on 
those with treatment status and timely institution of treatments in cases where 
lipid profile abnormalities persist. 
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Correlates of dyslipidemia among HIV infected children by treatment status
Correlates of dyslipidemia among children with HIV infection was assessed by 
treatment status using univariable and multivariable logistic regression models. 
Children on treatment had better anthropometric indices as compared to treatment 
naïve counterparts (Table 3 in Paper V). HAZ was the only independent predictor 
of dyslipidemia among treatment naïve children (Table 4 of Paper V). 
Furthermore, duration of treatment was briefer in those with treatment experience 
and who had dyslipidemia (median=49 months, Q1-Q3: (21.0 – 78.0) as compared 
to those without (median= 60 months, Q1-Q3: (30.3 – 90.8) months, which was not 
statistically different (p=0.253). Total cholesterol and HDLc values were however 
significantly different with treatment experience ( Figure 1 of Paper V). Children 
who took cART for more than 5 years had a significantly lower total cholesterol 
when compared to treatment naïve subjects (p=0.003). 
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5 CONCLUDIONS AND RECOMMENDATION
Pretreatment HIV drug resistance was observed to be less common in Ethiopian 
HIV infected children, but its presence predict treatment failure during the first 
year of cART. The rates of PDR observed in our study population is similar to 
reports from sub Saharan African children with no PMTCT exposure [100]. Our 
findings of the burden of PDR can be taken as representative figures for the 
whole of Ethiopia as our study included HIV-infected children having different 
geographic locations, ethnic and sociodemographic attributes across two of the 
largest administrative regions of Ethiopia. 
Overall, our findings reveal that a high proportion of children with HIV infection 
from resource scarce settings can achieve virological suppression within the first 
year of cART. PDR is associated with worse virological suppression while a teno-
fovir based cART regimen is associated with better virological suppression within 
one year of treatment. The high prevalence of viral rebound in more than a third 
of the included children is worrying, but fewer patients exhibited sustained high 
viremia suggesting virologic treatment failure. We also demonstrated a considerable 
(81%) burden of HIVDR among children who were on a failing first line regimen 
in Ethiopia. This is especially important as it seriously limits potential treatment 
options. More alarmingly, for about a third of the children included in the study, 
none of the four locally available NRTIs were fully active to be used as second line. 
Regarding the safety of antiretroviral therapy, it was observed that abnormalities in 
liver enzyme tests tend to improve with time on treatment, while kidney function, 
assessed by GFR and BUN, tends to deteriorate progressively. Nevirapine based 
regimens are associated with more liver enzyme abnormalities but is not the case 
for renal function. Another safety parameter assessed in this PhD thesis was HIV 
and cART associated dyslipidemia. Low HDLc dyslipidemia and hypertriglyceri-
demia were observed to be common among both treatment experienced and naïve 
children and adolescents. However, treatment experience was associated with a 
significantly higher prevalence of any dyslipidemia.
Based on our results, an individualized patient care decision approach based on 
presence of pretreatment drug resistance mutations is recommended. Furthermore, 
the findings indicate the need for more studies with larger sample size to under-
stand the relationship between PDR, treatment regimen and virologic response.
The use of PI based regimens as first line drugs for children is supported by our 
findings of high burden of resistance to nevirapine and EFV which are the NNRTIs 
currently accessible for pediatric first line treatment in Ethiopia [41, 42]. On the 
other hand, we observed a relatively low burden of resistance (~5%) to NRTI 
drugs and none of the PI class drugs showed resistance mutations, which supports 
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using NRTIs in first line regimens. Nonetheless, affordable and expanded access 
to alternative treatment options including integrase inhibitors is an urgent need in 
resource limited settings, given the emergence of dual class resistance, notwith-
standing in a minority (5%) of cases.
To accelerate the fight to end the HIV/AIDS epidemic, an integrated and effective 
clinical care of HIV infected children living in resource constrained settings is very 
important. Expanding access to HIV treatment options and to routine virologic 
resistance testing in resource poor settings like Ethiopia is greatly needed. Such 
services would improve meeting basic human rights needs and improve prognosis 
of vulnerable children in such settings. 
The safety related analysis and findings of the project emphasizes the need for 
routine monitoring of hepatic and renal function tests as well as screening for 
metabolic disorders. Monitoring children for adverse events of long-term cART, 
including dyslipidemia are of utmost importance to ensure better quality of life 
for HIV infected children. It is important to consider institution of The presence 
of lifestyle modifications and lipid lowering drugs in a small group of children to 
reduce risks of cardiovascular accidents.
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